Long-Term Safety and Efficacy of BMS-986165 in Subjects with Psoriasis

An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224973

Enrollment

Registered

2019-12-02

Start date

2019-08-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate-to-Severe Plaque Psoriasis

Interventions

BMS-986165 will be administered orally at a dose of 6 mg QD.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis -Women must not be pregnant, lactating, or breastfeeding

Exclusion criteria

Exclusion criteria: -Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study. -To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.

Design outcomes

Primary

Measure	Time frame
Incidence of Adverse Events (AE) and Serious Adverse Events (SAE) [ Time Frame: 96 weeks ]	—

Secondary

Measure	Time frame
-static Physician Global Assessment (sPGA)0/1 response [ Time Frame: 96 weeks ] -Psoriasis Area and Severity Index (PASI) 75 response [ Time Frame: 96 weeks ]	—

Countries

Contacts

Public ContactEleni Vritzali

Bristol-Myers Squibb

MG-JP-RCO-JRCT@bms.com+81-120-093-507

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026